Nagao M, Sato Y and Yamauchi A
Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is correlated to reduced risk of developing cancer through reduction of inflammation, which is an important risk factor for cancer. Several studies have investigated the possible association between polymorphisms in the gene encoding inflammatory cytokines and use of NSAIDs with cancer risk; however, these studies have obtained mixed results. Therefore, we performed a meta-analysis to evaluate the association between genetic polymorphisms of Interleukin (IL) 1B, IL6, IL8, and IL10, and NSAID usage with respect to cancer risk. We conducted a comprehensive search in PubMed through May 2013. Odds Ratios (ORs) with corresponding 95% Confidence Intervals (CIs) were calculated using the fixed-effect or the random-effect model. Comprehensive search of databases revealed eight studies fulfilling the inclusion criteria. For IL6 rs1800795, the minor allele carriers demonstrated a significantly decreased cancer risk compared to those homozygous for the major allele (GG) among NSAID users (OR=0.80, 95% CI=0.68-0.95). For IL8 rs4073, NSAID users had a significantly decreased cancer risk compared to the non-NSAID users (OR=0.71, 95% CI=0.53-0.96) among those homozygous for the major allele (TT). For the IL1B rs1143627 and IL10 rs1800872 SNPs, we did not observe any significant difference. We identified a correlation between the polymorphisms IL6 rs1800795 and IL8 rs4073 and NSAID usage in decreased cancer risk.
Partagez cet article
English 
Spanish 
Chinese 
Russian 
German 
Japanese 
Portuguese 
Hindi 